Table 1.
Relation between miR-607 expression and clinicopathological characteristics of PDAC patients.
| Variables | Number | miR-607 expression | P | |
|---|---|---|---|---|
| Low (n = 25, %) | High (n = 25, %) | |||
| Age (years) | 0.087 | |||
| <60 | 22 | 8 (16%) | 14 (28%) | |
| ≥60 | 28 | 17 (34%) | 11 (22%) | |
|
| ||||
| Gender | 0.083 | |||
| Male | 30 | 12 (24%) | 18 (36%) | |
| Female | 20 | 13 (26%) | 7 (14%) | |
|
| ||||
| Tumor size (cm) | 0.355 | |||
| <3 | 15 | 9 (18%) | 6 (12%) | |
| ≥3 | 35 | 16 (32%) | 19 (38%) | |
|
| ||||
| Tumor differentiation | 0.771 | |||
| Well - moderate | 19 | 10 (20%) | 9 (18%) | |
| Poor | 31 | 15 (30%) | 16 (32%) | |
|
| ||||
| Clinical stage | 0.136 | |||
| I-II | 17 | 6 (12%) | 11 (22%) | |
| III-IV | 33 | 19 (38%) | 14 (28%) | |
|
| ||||
| T Stage | 0.152 | |||
| T1-T2 | 21 | 13 (26%) | 8 (16%) | |
| T3-T4 | 29 | 12 (24%) | 17 (34%) | |
|
| ||||
| Lymphatic metastasis | 0.002 | |||
| Negative | 14 | 2 (4%) | 12 (24%) | |
| Positive | 36 | 23 (46%) | 13 (26%) | |
|
| ||||
| Perineural invasion | 0.004 | |||
| Negative | 22 | 6 (12%) | 16 (32%) | |
| Positive | 28 | 19 (38%) | 9 (18%) | |
|
| ||||
| Liver metastasis | 0.018 | |||
| Negative | 45 | 20 (40%) | 25 (50%) | |
| Positive | 5 | 5 (10%) | 0 (0%) | |
|
| ||||
| CEA level (ng/mL) | 0.774 | |||
| <5 | 21 | 10 (20%) | 11 (22%) | |
| ≥5 | 29 | 15 (30%) | 14 (28%) | |
|
| ||||
| CA19-9 level (U/mL) | 0.333 | |||
| <35 | 13 | 8 (16%) | 5 (10%) | |
| ≥35 | 37 | 17 (34%) | 20 (40%) | |
PDAC: pancreatic ductal adenocarcinoma.